

ELCC 2020 Industry Satellite Symposium

# Targeting lung cancer: different approaches for different patients

Friday 17 April 2020, 13:00–14:00  
 Palexpo, Room A, Geneva, Switzerland



## Faculty and agenda



### Solange Peters (Chair)

*Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland*

**Extensive-stage SCLC: changing the paradigm with IO combinations**



### Johan Vansteenkiste

*University Hospital KU Leuven, Leuven, Belgium*

**Unresectable stage III NSCLC: clinical implementation of new approaches**



### David Planchard







*Institut Gustave Roussy, Villejuif, France*

**EGFRm NSCLC: targeted treatment options to improve outcomes in first-line locally advanced or mNSCLC and beyond progression**

### Audience Q&A

Refreshments are available prior to the symposium

## AstraZeneca's commitment to sustainability

 <p><b>\$19 million</b> invested in environmental efficiency projects (NRRGG Fund)</p>	 <p><b>CPD A Lists</b> one of six companies worldwide to achieve double A listing for Climate Change and Water Security for three consecutive years</p>	 <p><b>61% of our power</b> is sourced or generated from renewable sources</p>	 <p><b>100% of API</b> (Active Pharmaceutical Ingredient) discharges from sites were safe</p>	 <p><b>8% reduction</b> in our water use since 2015</p>	 <p><b>7% of our fleet</b> of vehicles is Europe, North America and Japan is hybrid, plug-in or electric, up from &lt;1% in 2017</p>
---	--	---	--	--	---



AstraZeneca is investing up to \$1 billion in a commitment to become carbon neutral by 2025 and carbon negative by 2030. Find out more about AstraZeneca's Commitment to Sustainability at our website

This scientific satellite symposium is funded and organised by AstraZeneca

VPM ID: CH-2252 | Date of preparation: February 2020 | Expiry date: July 2020

AstraZeneca, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK